Amgen Inc. (NASDAQ:AMGN) is Brown Lisle Cummings Inc.’s 9th Largest Position

Brown Lisle Cummings Inc. reduced its holdings in Amgen Inc. (NASDAQ:AMGNFree Report) by 2.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 22,236 shares of the medical research company’s stock after selling 456 shares during the period. Amgen comprises 1.7% of Brown Lisle Cummings Inc.’s holdings, making the stock its 9th biggest position. Brown Lisle Cummings Inc.’s holdings in Amgen were worth $5,796,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in AMGN. Capital Performance Advisors LLP acquired a new stake in Amgen in the third quarter valued at approximately $25,000. Legacy Investment Solutions LLC acquired a new stake in Amgen in the 3rd quarter valued at $29,000. Matrix Trust Co purchased a new position in Amgen during the third quarter valued at $36,000. Heck Capital Advisors LLC acquired a new stake in shares of Amgen in the fourth quarter valued at about $36,000. Finally, Livelsberger Financial Advisory purchased a new position in shares of Amgen in the third quarter valued at approximately $56,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Up 1.2 %

AMGN opened at $288.87 on Tuesday. The business has a 50 day moving average price of $271.06 and a two-hundred day moving average price of $304.11. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The company has a market cap of $155.28 billion, a PE ratio of 36.99, a P/E/G ratio of 2.87 and a beta of 0.56. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a dividend of $2.38 per share. The ex-dividend date is Friday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a dividend yield of 3.30%. Amgen’s dividend payout ratio (DPR) is currently 115.24%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on AMGN. Piper Sandler decreased their target price on shares of Amgen from $344.00 to $310.00 and set an “overweight” rating on the stock in a research note on Thursday, January 2nd. Cantor Fitzgerald restated an “overweight” rating and issued a $405.00 price objective on shares of Amgen in a report on Tuesday, October 22nd. Jefferies Financial Group reissued a “buy” rating and issued a $380.00 target price on shares of Amgen in a research report on Tuesday, November 12th. StockNews.com cut Amgen from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Finally, Truist Financial lowered their target price on Amgen from $333.00 to $298.00 and set a “hold” rating for the company in a report on Wednesday, January 8th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $314.00.

Read Our Latest Report on Amgen

Amgen Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Featured Stories

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.